Arcoxia (Etoricoxib)
Selective COX-2 Inhibitor for Arthritis, Gout & Pain
Arcoxia (etoricoxib) is a selective cyclo-oxygenase-2 (COX-2) inhibitor belonging to the coxib class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is used to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gout, and short-term pain after dental surgery in patients aged 16 years and older. Unlike traditional NSAIDs such as ibuprofen or naproxen, etoricoxib selectively blocks COX-2 while largely sparing COX-1, which may reduce the risk of gastrointestinal side effects. Arcoxia requires a prescription and is taken once daily. It is not approved for use in the United States but is widely available in Europe, Latin America, and Asia.
Quick Facts
Key Takeaways
- Etoricoxib is a selective COX-2 inhibitor that reduces pain, inflammation, and swelling by targeting the COX-2 enzyme while sparing COX-1, potentially reducing gastrointestinal side effects compared to traditional NSAIDs.
- It has a long half-life of approximately 22 hours, allowing convenient once-daily dosing for all approved indications.
- Arcoxia is approved for osteoarthritis (30–60 mg/day), rheumatoid arthritis and ankylosing spondylitis (60–90 mg/day), acute gout (120 mg/day for up to 8 days), and post-dental surgery pain (90 mg/day for up to 3 days).
- It is contraindicated in patients with established cardiovascular disease, uncontrolled hypertension, severe liver or kidney disease, inflammatory bowel disease, pregnancy, and breastfeeding.
- The most common side effect is stomach pain; serious but less common risks include cardiovascular events, elevated blood pressure, and liver problems. Regular medical monitoring is recommended.
What Is Arcoxia and What Is It Used For?
Arcoxia belongs to the coxib subclass of nonsteroidal anti-inflammatory drugs (NSAIDs), a group of medicines designed to selectively inhibit cyclo-oxygenase-2 (COX-2). The COX-2 enzyme is primarily responsible for producing prostaglandins at sites of tissue damage and inflammation. By selectively blocking COX-2, etoricoxib reduces prostaglandin synthesis in inflamed tissues, thereby providing effective pain relief, reducing swelling, and lowering fever, while having a significantly lesser effect on COX-1—the enzyme that helps protect the stomach lining and supports normal platelet function.
Etoricoxib was developed by Merck & Co. and first received marketing authorization in 2002. It is now available in over 80 countries worldwide, including throughout Europe (authorized by the European Medicines Agency), Latin America, and Asia-Pacific. Notably, etoricoxib has not received FDA approval for the United States market; the FDA declined approval in 2007, requesting additional cardiovascular safety data. Nevertheless, it remains one of the most widely prescribed selective COX-2 inhibitors globally, with extensive clinical trial data supporting its efficacy and safety profile.
Approved Indications
Etoricoxib is licensed for the treatment of several chronic and acute inflammatory conditions in patients aged 16 years and older. The approved indications include:
- Osteoarthritis – The most common form of arthritis, caused by gradual breakdown of the cartilage that cushions the ends of bones in joints. This leads to pain, stiffness, swelling, and reduced joint mobility. Etoricoxib effectively manages the chronic pain and inflammation associated with osteoarthritis.
- Rheumatoid arthritis – A chronic autoimmune inflammatory disease that affects the joints, causing pain, stiffness, swelling, and progressive loss of function. It can also involve inflammation in other parts of the body. Etoricoxib provides sustained relief of joint symptoms.
- Ankylosing spondylitis – A chronic inflammatory disease primarily affecting the spine and large joints, causing pain and stiffness in the back. NSAIDs, including etoricoxib, are first-line pharmacological treatment for this condition according to European League Against Rheumatism (EULAR) and Assessment of SpondyloArthritis international Society (ASAS) guidelines.
- Acute gouty arthritis – Gout is a joint disease characterized by sudden, recurrent attacks of severe pain, inflammation, and redness caused by the deposition of monosodium urate crystals in joint tissues. Etoricoxib 120 mg once daily is effective for relieving the acute pain of gout flares.
- Moderate pain after dental surgery – Etoricoxib is approved for short-term management of moderate pain following dental procedures, providing an alternative to opioid analgesics in this setting.
How Etoricoxib Works
Etoricoxib exerts its therapeutic effects through highly selective inhibition of the COX-2 enzyme. In human whole blood assays, etoricoxib demonstrates a COX-1 to COX-2 selectivity ratio of approximately 106-fold, making it one of the most COX-2 selective agents in clinical use. This high selectivity means that at therapeutic doses, etoricoxib produces potent anti-inflammatory and analgesic effects through COX-2 inhibition while having minimal impact on COX-1-mediated physiological processes such as gastric mucosal protection, platelet aggregation, and renal hemodynamics.
After oral administration, etoricoxib is rapidly and almost completely absorbed, with an oral bioavailability of approximately 100%. Peak plasma concentrations are typically reached within 1 hour, and its elimination half-life of approximately 22 hours supports once-daily dosing across all approved indications. The drug is extensively metabolized in the liver, primarily by CYP3A4 enzymes, and approximately 70% of an oral dose is excreted in the urine as metabolites. Etoricoxib is highly protein-bound (approximately 92%) and has a volume of distribution of approximately 120 liters in humans.
The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) program, one of the largest NSAID outcome studies ever conducted with over 34,700 patients, demonstrated that etoricoxib had a comparable cardiovascular safety profile to diclofenac while showing significantly fewer upper gastrointestinal events, including clinical upper GI events such as perforations, obstructions, and bleeding. This landmark study, published in The Lancet in 2007, has been central to the regulatory assessment of etoricoxib's benefit-risk profile.
What Should You Know Before Taking Arcoxia?
Before starting treatment with Arcoxia, it is essential to carefully review the contraindications and precautions with your doctor. Etoricoxib, like all NSAIDs, carries certain risks that must be weighed against its benefits. Your doctor will consider your complete medical history, current medications, and individual risk factors before prescribing this medicine.
Contraindications
Arcoxia must not be taken in the following situations. If any of these apply to you, inform your doctor before starting treatment:
- Allergy to etoricoxib or any excipient – If you have experienced allergic reactions to etoricoxib or any other ingredient in the tablets.
- NSAID hypersensitivity – If you have had allergic reactions (including asthma, urticaria, rhinitis, or angioedema) after taking aspirin or any other NSAID, including other COX-2 inhibitors.
- Active peptic ulcer or gastrointestinal bleeding – If you currently have a stomach ulcer or bleeding in the stomach or intestines.
- Severe liver disease – Advanced hepatic impairment significantly alters drug metabolism and increases the risk of toxicity.
- Severe kidney disease – Estimated creatinine clearance below 30 ml/min.
- Inflammatory bowel disease – Active Crohn's disease, ulcerative colitis, or colitis.
- Uncontrolled hypertension – Blood pressure that has not been adequately controlled with treatment. If you are uncertain whether your blood pressure is under control, check with your doctor.
- Established cardiovascular disease – Including heart failure (moderate or severe), angina pectoris (chest pain), history of myocardial infarction, coronary artery bypass graft surgery, peripheral arterial disease, or any form of cerebrovascular disease (stroke or transient ischemic attack).
- Pregnancy and breastfeeding – Arcoxia must not be used during pregnancy or while breastfeeding.
- Age under 16 years – Not approved for use in children and adolescents below 16 years of age.
Warnings and Precautions
Even when Arcoxia is not strictly contraindicated, there are many situations in which extra caution is necessary. Speak to your doctor before using etoricoxib if any of the following apply:
Selective COX-2 inhibitors may be associated with a small increased risk of cardiovascular thrombotic events, including myocardial infarction and stroke, particularly when used at high doses for prolonged periods. Use the lowest effective dose for the shortest duration necessary. Arcoxia must not be used in patients with established cardiovascular disease or uncontrolled hypertension.
- History of gastrointestinal problems – Previous stomach or duodenal ulcers, gastrointestinal bleeding, or peptic ulcer disease increase the risk of recurrence.
- Dehydration – If you are dehydrated (for example, after prolonged vomiting or diarrhea), rehydration is recommended before starting etoricoxib.
- Fluid retention or edema – Etoricoxib may cause sodium and fluid retention, which can worsen pre-existing edema or heart failure.
- History of heart failure or cardiac disease – Even without established cardiovascular disease, discuss your cardiac history with your doctor.
- Hypertension – Arcoxia can increase blood pressure in some patients, particularly at higher doses. Your doctor should monitor your blood pressure regularly during treatment.
- Liver or kidney disease – Even mild to moderate impairment requires dose adjustment and careful monitoring.
- Infections – Etoricoxib may mask fever and other signs of infection, potentially delaying appropriate treatment.
- Cardiovascular risk factors – Diabetes mellitus, high cholesterol, or smoking increase your baseline risk for cardiovascular events.
- Elderly patients (over 65 years) – Arcoxia works equally well in older adults, but physicians should monitor treatment more closely due to the increased vulnerability to adverse effects in this population.
Pregnancy and Breastfeeding
Arcoxia is contraindicated during pregnancy. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, do not take this medicine. Discontinue Arcoxia immediately and consult your doctor if you become pregnant during treatment. NSAIDs, including selective COX-2 inhibitors, can have adverse effects on fetal development, particularly on the cardiovascular and renal systems, especially during the third trimester.
It is not known whether etoricoxib passes into human breast milk. If you are breastfeeding or planning to breastfeed, consult your doctor before taking Arcoxia. If you do take Arcoxia, you should not breastfeed. Etoricoxib is also not recommended for women who are trying to conceive, as it may impair fertility.
Driving and Using Machines
Dizziness and drowsiness have been reported by some patients taking etoricoxib. If you experience either of these effects, do not drive, operate machinery, or perform activities requiring alertness until the symptoms resolve. Always assess your own fitness before engaging in such activities when taking any medication.
Important Information About Excipients
Arcoxia tablets contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The tablets also contain less than 1 mmol (23 mg) of sodium per tablet, meaning they are essentially sodium-free.
How Does Arcoxia Interact with Other Drugs?
Drug interactions are an important consideration when taking etoricoxib. The metabolism of etoricoxib occurs primarily through CYP3A4 in the liver, and it can affect the pharmacokinetics and pharmacodynamics of several other medications. Conversely, drugs that strongly induce CYP3A4 (such as rifampicin) can reduce etoricoxib plasma concentrations. Always inform your doctor and pharmacist about all medications you are currently taking, including over-the-counter medicines and herbal supplements.
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Advice |
|---|---|---|
| Warfarin and other anticoagulants | Etoricoxib may enhance the anticoagulant effect, increasing INR and bleeding risk. | Close INR monitoring when starting, adjusting, or stopping etoricoxib. |
| Lithium | NSAIDs reduce renal lithium clearance, raising plasma levels and toxicity risk. | Monitor lithium plasma levels. Dose adjustment may be necessary. |
| Methotrexate | NSAIDs may reduce renal clearance of methotrexate, increasing toxicity risk. | Monitor for methotrexate-related adverse effects, especially at high doses. |
| Ciclosporin / Tacrolimus | Increased nephrotoxicity risk due to additive renal prostaglandin inhibition. | Monitor renal function closely during concurrent use. |
| ACE inhibitors & ARBs | Reduced antihypertensive effect and increased risk of acute kidney injury. | Monitor blood pressure and renal function. Ensure adequate hydration. |
| Diuretics | Reduced diuretic and antihypertensive effects through sodium retention. | Monitor blood pressure and fluid balance. |
| Digoxin | NSAIDs may increase digoxin plasma levels, raising toxicity risk. | Monitor digoxin levels and watch for signs of toxicity. |
Other Notable Interactions
- Rifampicin – A potent CYP3A4 inducer that can reduce etoricoxib plasma concentrations by approximately 65%, potentially reducing its therapeutic effect.
- Oral contraceptives – Etoricoxib 120 mg increased ethinylestradiol plasma concentrations by 50–60%, which may increase the risk of thromboembolic events. Consider this interaction especially in women with other risk factors for thrombosis.
- Hormone replacement therapy (HRT) – Similar to oral contraceptives, the combination may increase the risk of adverse effects from estrogen therapy.
- Aspirin (low-dose) – Low-dose aspirin for cardiovascular prevention can be taken with etoricoxib, but the combination increases gastrointestinal bleeding risk. Do not take high-dose aspirin or other NSAIDs together with Arcoxia.
- Minoxidil – Etoricoxib may reduce the antihypertensive effect of minoxidil.
- Salbutamol (oral) – Etoricoxib may increase plasma concentrations of oral salbutamol formulations.
Arcoxia can be taken with or without food. The effect may be achieved faster if taken on an empty stomach, as food can slightly delay absorption. This is not clinically significant for most indications.
What Is the Correct Dosage of Arcoxia?
Always take Arcoxia exactly as your doctor has prescribed. It is important to use the lowest possible dose that effectively controls your symptoms, and treatment should not be continued longer than necessary. The risk of cardiovascular events may increase with higher doses and longer duration of use. Your doctor may periodically reassess your treatment.
Adults
Etoricoxib is available in four tablet strengths (30 mg, 60 mg, 90 mg, and 120 mg), and the prescribed dose depends on the specific condition being treated:
| Indication | Recommended Dose | Maximum Dose | Duration |
|---|---|---|---|
| Osteoarthritis | 30 mg once daily | 60 mg once daily | Long-term (as needed) |
| Rheumatoid arthritis | 60 mg once daily | 90 mg once daily | Long-term (as needed) |
| Ankylosing spondylitis | 60 mg once daily | 90 mg once daily | Long-term (as needed) |
| Acute gout | 120 mg once daily | 120 mg once daily | Max 8 days |
| Post-dental surgery pain | 90 mg once daily | 90 mg once daily | Max 3 days |
Children and Adolescents
Arcoxia is not approved for use in children and adolescents under 16 years of age. There is insufficient clinical data on safety and efficacy in this age group.
Elderly Patients
No dose adjustment is necessary for elderly patients. Etoricoxib is equally effective in older adults as in younger patients. However, as with all NSAIDs, particular caution is warranted in patients over 65 years due to increased vulnerability to gastrointestinal, cardiovascular, and renal adverse effects. Your doctor may wish to monitor your treatment more closely.
Patients with Liver Disease
- Mild liver disease (Child-Pugh score 5–6) – Do not exceed 60 mg daily.
- Moderate liver disease (Child-Pugh score 7–9) – Do not exceed 30 mg daily.
- Severe liver disease – Arcoxia is contraindicated.
Missed Dose
If you forget to take a dose, simply resume your regular schedule the following day. Do not take a double dose to compensate for a missed one.
Overdose
Never take more tablets than your doctor has prescribed. If you or someone else has taken more than the recommended dose, contact your local poison control center or seek emergency medical attention immediately. Etoricoxib cannot be removed by dialysis. There is no specific antidote; treatment is supportive and symptomatic.
What Are the Side Effects of Arcoxia?
Like all medicines, Arcoxia can cause side effects, although not everyone experiences them. It is important to recognize the warning signs that require immediate medical attention.
- Shortness of breath, chest pain, or swelling of the legs or feet (cardiovascular or heart failure signs)
- Yellowing of the skin or eyes (jaundice)—signs of liver damage
- Severe or persistent abdominal pain, or black (tarry) stools—signs of gastrointestinal bleeding
- Allergic reaction including skin ulcers or blisters, swelling of the face, lips, tongue, or throat causing difficulty breathing
Very Common
May affect more than 1 in 10 people
- Stomach pain (abdominal pain)
Common
May affect up to 1 in 10 people
- Dry socket (post-extraction inflammation)
- Swelling of legs/feet due to fluid retention (edema)
- Dizziness, headache
- Palpitations, arrhythmia
- Elevated blood pressure
- Wheezing or shortness of breath (bronchospasm)
- Constipation, bloating, gastritis, heartburn, diarrhea, dyspepsia, nausea, vomiting
- Esophageal inflammation, mouth ulcers
- Altered liver function tests
- Bruising
- Weakness, fatigue, flu-like symptoms
Uncommon
May affect up to 1 in 100 people
- Gastroenteritis, upper respiratory infection, urinary tract infection
- Changes in blood counts (decreased red cells, white cells, or platelets)
- Hypersensitivity reactions (including severe hives)
- Appetite changes, weight gain
- Anxiety, depression, reduced mental sharpness, hallucinations
- Taste changes, insomnia, numbness or tingling, drowsiness
- Blurred vision, eye irritation
- Tinnitus, vertigo
- Atrial fibrillation, rapid heart rate, heart failure, angina, heart attack
- Flushing, stroke, mini-stroke (TIA), severe blood pressure elevation, vasculitis
- Cough, nosebleed
- Dry mouth, gastric ulcer, pancreatitis, irritable bowel
- Facial swelling, skin rash, itching, redness
- Muscle cramps, muscle pain/stiffness
- Elevated potassium, altered kidney function, serious kidney impairment
- Chest pain
Rare
May affect up to 1 in 1,000 people
- Angioedema or anaphylaxis (life-threatening allergic reactions)
- Confusion, restlessness
- Hepatitis (liver inflammation)
- Low blood sodium (hyponatremia)
- Liver failure, jaundice
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
Cardiovascular Risk
All NSAIDs, including selective COX-2 inhibitors, carry warnings about potential cardiovascular risks. The MEDAL study compared etoricoxib with diclofenac in over 34,700 patients over a mean treatment period of 18 months and found comparable rates of thrombotic cardiovascular events between the two drugs. The EMA has concluded that the cardiovascular risk of etoricoxib is comparable to that of other NSAIDs within approved dose ranges. Nevertheless, the risk may increase with dose and duration of use, which is why treatment should always employ the lowest effective dose for the shortest necessary period.
Blood Pressure Effects
Etoricoxib can raise blood pressure in a dose-dependent manner. In the MEDAL program, a higher proportion of patients on etoricoxib discontinued treatment due to hypertension-related adverse events compared to diclofenac. Blood pressure should be monitored within two weeks of starting treatment and periodically thereafter. If blood pressure rises significantly, your doctor may need to adjust your treatment or discontinue etoricoxib.
If you experience any side effects, including those not listed here, report them to your healthcare provider. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the Yellow Card Scheme in the UK, or the EMA EudraVigilance system). Reporting side effects helps monitor the ongoing safety of medicines.
How Should You Store Arcoxia?
Proper storage ensures the medication remains effective and safe. Follow these guidelines:
- Keep out of the reach and sight of children – Accidental ingestion by children is a medical emergency.
- Check the expiration date – Do not use after the date (EXP) printed on the carton. The expiration date refers to the last day of the indicated month.
- Bottles – Keep tightly closed. The product is moisture-sensitive. Do not swallow the desiccant container(s) inside the bottle.
- Blister packs – Store in the original packaging to protect from moisture.
- Proper disposal – Do not discard in household waste or flush down the drain. Return unused tablets to a pharmacy or use a medication take-back program.
What Does Arcoxia Contain?
Active Ingredient
Each film-coated tablet contains etoricoxib. The available strengths are:
- 30 mg – Blue-green, apple-shaped, biconvex tablets marked “ACX 30” / “101”.
- 60 mg – Dark green, apple-shaped, biconvex tablets marked “ARCOXIA 60” / “200”.
- 90 mg – White, apple-shaped, biconvex tablets marked “ARCOXIA 90” / “202”.
- 120 mg – Light green, apple-shaped, biconvex tablets marked “ARCOXIA 120” / “204”.
Inactive Ingredients (Excipients)
- Tablet core: Calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate, microcrystalline cellulose.
- Film coating: Carnauba wax, lactose monohydrate, hypromellose, titanium dioxide (E171), triacetin. The 30 mg, 60 mg, and 120 mg tablets also contain yellow iron oxide (E172) and indigo carmine (E132).
Arcoxia contains lactose monohydrate in the film coating. If you have lactose intolerance, contact your doctor before use. The sodium content is less than 1 mmol (23 mg) per tablet, meaning Arcoxia is essentially sodium-free.
Available Pack Sizes
Arcoxia is available in blister packs and bottles of various sizes. Common blister packs include 7, 14, 28, and 98 tablets. Bottles contain 30 or 90 tablets with desiccant. Unit-dose aluminum blisters are available in packs of 5, 50, or 100 tablets for the 60 mg, 90 mg, and 120 mg strengths. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Arcoxia
Arcoxia (etoricoxib) is a selective COX-2 inhibitor used to treat pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. It is also used for short-term treatment of moderate pain after dental surgery. It is available in 30 mg, 60 mg, 90 mg, and 120 mg tablets and is taken once daily. It requires a prescription in all markets.
Arcoxia selectively blocks the COX-2 enzyme involved in inflammation while largely sparing COX-1, which protects the stomach lining. Traditional NSAIDs like ibuprofen and naproxen block both COX-1 and COX-2, which may lead to more gastrointestinal side effects. Arcoxia has a long half-life of about 22 hours, allowing once-daily dosing, compared to two to four times daily for ibuprofen. However, selective COX-2 inhibitors require careful cardiovascular risk assessment before use.
Yes, Arcoxia 120 mg once daily is approved for acute gouty arthritis, limited to a maximum of 8 days. Clinical studies have shown etoricoxib 120 mg to be as effective as indomethacin 50 mg three times daily for acute gout, but with fewer gastrointestinal side effects. Arcoxia is not intended for long-term gout prophylaxis or uric acid lowering.
No, etoricoxib is not FDA-approved and is not available in the United States. The FDA declined approval in 2007, citing cardiovascular safety concerns relative to existing alternatives. However, etoricoxib is approved in over 80 countries, including throughout Europe (EMA-authorized), Latin America, and Asia-Pacific.
The most common side effect is stomach pain (very common, more than 1 in 10). Common side effects include headache, dizziness, palpitations, elevated blood pressure, gastrointestinal symptoms (heartburn, nausea, diarrhea, constipation, bloating), swelling of legs/feet due to fluid retention, bruising, fatigue, and flu-like symptoms. Most are mild to moderate and resolve after stopping the medication.
Arcoxia can be taken with blood pressure medications, but it may reduce their effectiveness. ACE inhibitors, ARBs, and diuretics may become less effective due to etoricoxib's effects on sodium retention. Etoricoxib can also raise blood pressure. Your doctor should monitor blood pressure within two weeks of starting treatment and regularly thereafter. Adequate hydration is important to reduce the risk of acute kidney injury.
References
All information is based on current international medical guidelines, regulatory documents, and peer-reviewed research. No commercial funding was involved.
- Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the MEDAL programme. The Lancet. 2006;368(9549):1771–1781. doi:10.1016/S0140-6736(06)69666-9
- European Medicines Agency (EMA). Arcoxia (etoricoxib) – Summary of Product Characteristics. Available at: www.ema.europa.eu
- Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. The Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9
- National Institute for Health and Care Excellence (NICE). NSAIDs – prescribing issues. 2024. Available at: cks.nice.org.uk
- British National Formulary (BNF). Etoricoxib Monograph. Available at: bnf.nice.org.uk
- Dougados M, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896–904.
- Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of etoricoxib 120 mg compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum. 2004;50(2):598–606.
- Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in the MEDAL programme. The Lancet. 2007;369(9560):465–473.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: www.who.int
- McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs. PLoS Med. 2011;8(9):e1001098.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology, rheumatology, and pain management. All content follows the GRADE evidence framework and adheres to international medical guidelines from EMA, WHO, NICE, and EULAR.
All medical claims are supported by Level 1A evidence from systematic reviews, meta-analyses of randomized controlled trials, and current clinical guidelines. Key sources include the MEDAL programme, CNT Collaboration meta-analysis, EMA product information, BNF monograph, and NICE clinical knowledge summaries.
iMedic receives no commercial funding from pharmaceutical companies. Our editorial content is entirely independent, with no advertising, sponsorship, or conflicts of interest. All content is reviewed according to our rigorous editorial standards.